FDA
-
-
-
-
-
-
-
Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes
-
-
-
-
-
-
-
Sunovion Resubmits New Drug Application for Apomorphine Sublingual Film
-
-
-
-
-
-
-
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
-
-
-
-
-
-
-
FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
-
-
-
-
-
-
-
Sunovion Announces Data Presentations Highlighting Broad Portfolio of Treatments for COPD at the American Thoracic Society International Conference 2018
-
-
-
-
-
-
-
Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson’s Disease
-
-
-
-
-
-
-
Sunovion Announces Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder is Now Available in the United States
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

